Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Indeed, in the current study breast cancer patients with a BRCA-like CGH tumor had a markedly better OS after adjuvant HD-CTC than after conventional chemotherapy; this selective benefit was not present in patients with a non-BRCA-like CGH tumor, as confirmed by a highly significant test for interaction.

also in 132,142 other papers

The BRCA-like CGH status retained its predictive capacity within the following subgroups: TNBC patients (Table 2 , Figures 2 C and 2 D), ER-positive patients (Table 2 , Figures 2 E and 2 F), patients younger than 45 years (Figure S4 in Additional file 1 , Table S6 in Additional file 1 ), and showed a strong trend in patients with histological grade III tumors only (Figure S4 in Additional file 1 , Table S6 in Additional file 1 ).

also in 5,725 other papers